Micro-x Ltd. · ASX:MX1
Micro-x — Q1 FY27 Earnings Presentation
17 slides from Micro-x's earnings presentation, Nov 4, 2026
Slide 1: ASX: MX1 Quarterly Results
For personal use only ASX: MX1 Quarterly Results 4 November 2026
Slide 2: Important Notice
I M P O R T A N T N O T I C E For personal use only T H I S P R E S E N T A T I O N H A S B E E N A U T H O R I S E D F O R R E L E A S E B Y T H E B O A R D O F M I C R O - X L I M I T E D S C O P E & L I M I T A T I O N S This Presentation has been prepared by Micro-X Limited (Micro-X or the Compa
Slide 3: Important Notice - Continued
I M P O R T A N T N O T I C E - C O N T I N U E D For personal use only N O T I N V E S T M E N T A D V I C E The information contained in this Presentation is not financial product, investment, legal, taxation or other advice or any recommendation to acquire securities in the Company. No reliance m
Slide 4: Quarter at a Glance
Q U A R T E R A T A G L A N C E For personal use only Early progress against the strategic reset1 Rover momentum Medical CT milestones Funded development Costs and cash 10 units First human Head CT $1.6M $3M+ ordered in the September images shared ARPA-H milestone payment annualised cost savings qua
Slide 5: Who We Are
W H O W E A R E For personal use only Leading the world in carbon nanotube X-ray medical imaging WHAT WE HAVE BUILT WHAT IT HAS ENABLED WHAT COMES NEXT NEX Technology Platform Commercial Product Rover Sales Growth Proprietary core technology: Rover: Scalable, profitable business: • CNT x-ray • FDA &
Slide 6: Company Overview
C O M P A N Y O V E R V I E W For personal use only A vision to transform medical imaging Purpose Creating revolutionary X-ray imaging to better lives Commercial Opportunity • Significant market opportunity beyond conventional medical imaging Vision • Opportunities in emerging economies, rural Advan
Slide 7: Micro-X Strategic Plan
M I C R O - X S T R A T E G I C P L A N For personal use only Strategic reset being implemented from the beginning of FY27 under new leadership Grow Rover Sales 1 • Establish scalable and profitable business to generate revenue and support future CT • Establish Micro-X brand and market presence in M
Slide 8: Rover Sales
PRIORITY 1 · GROW ROVER SALES R O V E R S A L E S For personal use only Strongest quarter of Rover orders outside the Malaysian tender 10 UNITS ORDERED1 September 2026 quarter 7 UNITS ORDERED1 October 2026, post quarter Broad geographic demand Orders across the US, EMEA and Asia Pacific Strategy gai
Slide 9: Launch of RoverX
PRIORITY 1 · GROW ROVER SALES R O V E R X For personal use only Launch of RoverX – more of what matters Launch Plan Released in October Roadshow demo in Las Vegas focused on Radiographer Appreciation week New features focused on customer feedback Highlight the diversity of applications in US Higher
Slide 10: Head CT
PRIORITY 2 · FOCUS ON MEDICAL CT H E A D C T For personal use only Demonstration of critical core technology New Tube Demonstrated Demonstrated new tube design to improve manufacturability at scale IGP Design Progressing Funded Development – design for integration into a real ambulance progressing o
Slide 11: Head CT: First human images unveiled
PRIORITY 2 · FOCUS ON MEDICAL CT H E A D C T For personal use only First human images unveiled Patient, Micro-X Head CT Same patient, conventional CT Patient, Micro-X Head CT Same patient, conventional CT First Human Images Shared Australian Stroke Alliance presented the first de-identified human He
Slide 12: Full Body CT
PRIORITY 2 · FOCUS ON MEDICAL CT F U L L B O D Y C T For personal use only New engineering prototype operational Milestone Passed $1.6M ARPA-H milestone payment received in the September 2026 quarter Prototype Operational Engineering prototype producing CT images of phantoms since October. Sandia Na
Slide 13: Development Projects
PRIORITY 3 · DELIVER FUNDED DEVELOPMENT PROGRAMS D E V E L O P M E N T P R O J E C T S For personal use only US Department of Homeland Security contract extension Two-Booth Checkpoint Built Two-booth self-screening checkpoint completed in Seattle, ahead of Department of Homeland Security (DHS) testi
Slide 14: Financials
FINANCIAL RESULTS F I N A N C I A L S For personal use only Quarter-end cash of $4.4M; pro forma $8.6M including note proceeds and anticipated R&D refund Quarterly cash flow summary Pro forma cash, before other post-quarter cash flows A$M Jun 2026 qtr Sep 2026 qtr Cash at start of quarter $3.5M $3.1
Slide 15: Staff Costs
PRIORITY 4 · REDUCE AND CONTROL COSTS S T A F F C O S T S For personal use only Underlying staff costs fell 5% to $3.7M, excluding one-off and timing items Staff costs, September 2026 quarter1 September 2026 quarter $4.7M −$0.5M 5% lower than the June quarter −$0.3M Underlying staff costs of $3.7M r
Slide 16: Outlook: December Quarter
OUTLOOK D E C E M B E R Q U A R T E R For personal use only Key milestones expected this quarter1 FULL BODY CT CORPORATE HEAD CT ROVERX FUNDING FUNDING Early November 12 November November 29 Nov – 3 Dec 1 December Dec quarter ARPA-H decision Annual General First fully Launch at RSNA2 Final $1M R&D T
Slide 17: Conclusion
C O N C L U S I O N For personal use only Strategic reset delivering early results Team packing the first RoverX for shipment to the US ARPA-H and core technology teams during the Sandia visit Progress delivered Execution priorities December-quarter milestones 10 Rover orders in the September quarte